George Washington University has collaborated with Moderna to test the safety of the first mRNA HIV vaccines and the immune responses of two participants in the Phase 1 clinical trial. Four institutions, including GW, have enrolled 56 HIV-negative adult participants for the vaccines’ clinical trials. The mRNA HIV vaccine aims to block the replication of HIV strains and stimulate the production of broadly neutralizing antibodies that control the virus within HIV-positive patients’ immune systems. Read more by clicking the link!
University administers first doses of mRNA HIV vaccine through Moderna partnership
Latest News
This was a phase 2, randomized, open-label, non-placebo controlled trial to evaluate two partial doses o the Modified Vaccinia Ankara-Bavarian Nordin (MVA-BN) vaccine for protection against mpox.
This was a phase 1, double-blind trial to examine the safety and immunogenicity of a replication-competent recombinant vesicular stomatitis virus-vectored vaccine to reduce the risk of infection and severe illness from Lassa Fever.
The GW VRU is pleased to share the findings from a Phase 2 clinical trial that evaluated the effects of omicron-based COVID-19 vaccines in providing an increased level of protection against COVID-19 infection. This study adds to the evidence that matching COVID-19 vaccines to the circulating…